NSIVX Performance — North Square Altrinsic International Equity Fund, Class I
Data updated: 2026-09-25
NSIVX returned +4.59% year to date and +13.49% over one year to May 2026. Annualised returns are +14.43% over 3 years and +6.78% over 5 years. The fund trailed its International Large Blend category average: $100 invested three years ago grew to $150, against $161 for the category, and to $113 over one year, against $122. Volatility over the past three years was 11.29% a year. In the 12 months to May 2026 the fund lost a net $28.5M, and assets reached $82.70M.
NSIVX Growth of $100
What $100 invested in North Square Altrinsic International Equity Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the International Large Blend category average over the same months.
| Period | NSIVX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $113 | $122 |
| 3 years (Jun 2023 – May 2026) | $150 | $161 |
| 5 years (Jun 2021 – May 2026) | $139 | $144 |
| Since data start (Dec 2020 – May 2026) | $155 | $166 |
NSIVX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +4.59% |
| 1 year | +13.49% |
| 3 years (annualised) | +14.43% |
| 5 years (annualised) | +6.78% |
NSIVX Annual Returns
Calendar-year total returns of North Square Altrinsic International Equity Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +4.59% |
| 2025 | +25.37% |
| 2024 | +3.62% |
| 2023 | +14.78% |
| 2022 | −8.07% |
| 2021 | +6.37% |
| 2020 (Dec–Dec) | +1.42% |
NSIVX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.0% | +5.7% | −8.1% | +3.4% | +2.1% | — | — | — | — | — | — | — |
| 2025 | +3.9% | +3.4% | +1.7% | +2.0% | +3.8% | +0.7% | −2.6% | +5.0% | +2.8% | −0.6% | +2.4% | +0.7% |
| 2024 | −0.4% | +1.2% | +3.7% | −2.9% | +3.4% | −2.7% | +4.7% | +3.0% | +1.7% | −5.0% | +0.2% | −2.8% |
| 2023 | +6.8% | −2.9% | +2.3% | +3.1% | −4.9% | +4.6% | +2.5% | −2.6% | −2.6% | −1.9% | +6.5% | +3.7% |
| 2022 | +0.2% | −2.7% | 0.0% | −5.4% | +2.0% | −7.6% | +1.5% | −4.6% | −7.6% | +6.1% | +12.4% | −0.8% |
| 2021 | −1.5% | +1.8% | +3.0% | +3.7% | +2.6% | −2.2% | −0.5% | +1.1% | −3.0% | +2.4% | −6.2% | +5.6% |
| 2020 | — | — | — | — | — | — | — | — | — | — | — | +1.4% |
NSIVX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 11.29%
- 3-year Sharpe ratio: 0.88 (vs 4.5% risk-free rate)
- Best month: +6.53% (Nov 2023)
- Worst month: −8.12% (Mar 2026)
NSIVX Fund Flows
Monthly money in and out of North Square Altrinsic International Equity Fund, from SEC Form N-PORT.
- 12-month net flow: −$28.5M
- 12-month gross sales (incl. reinvestments): $13.1M
- Sales ÷ redemptions: 0.32×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $572K | $652K | −$80K |
| Apr 2026 | $90K | $1.3M | −$1.2M |
| Mar 2026 | $12K | $235K | −$223K |
| Feb 2026 | $4K | $1.5M | −$1.5M |
| Jan 2026 | $1.1M | $1.9M | −$845K |
| Dec 2025 | $8.4M | $3.0M | $5.5M |
| Nov 2025 | $2.2M | $22.9M | −$20.7M |
| Oct 2025 | $385K | $345K | $41K |
| Sep 2025 | $51K | $7.8M | −$7.7M |
| Aug 2025 | $68K | $180K | −$112K |
| Jul 2025 | $42K | $1.2M | −$1.2M |
| Jun 2025 | $213K | $579K | −$366K |
NSIVX Assets Under Management
Net assets of North Square Altrinsic International Equity Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $82.70M |
| 2026-02-28 | $86.86M |
| 2025-11-30 | $85.12M |
| 2025-08-31 | $109.38M |
| 2025-05-31 | $107.81M |
| 2025-04-30 | $104.12M |
| 2025-01-31 | $119.80M |
| 2024-10-31 | $124.00M |
| 2024-07-31 | $123.96M |
| 2024-04-30 | $121.93M |
| 2024-01-31 | $118.75M |
| 2023-10-31 | $107.98M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.